Anakinra: a silver lining in COVID-19? - Critical Care
Oct 6, 2020 · Anakinra (IL-1α and IL-1β blocker) has shown greatly reduced mortality, need for invasive mechanical ventilation, and bettering oxygenation status in severe COVID-19 patients …
Transitions of blood immune endotypes and improved outcome …
Mar 12, 2024 · Background Endotype classification may guide immunomodulatory management of patients with bacterial and viral sepsis. We aimed to identify immune endotypes and …
Anakinra treatment in critically ill COVID-19 patients: a prospective ...
Dec 10, 2020 · Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases. We investigated the effects of anakinra on …
Fast recovery of cardiac function in PIMS-TS patients early using ...
Apr 7, 2021 · Second, the authors used anakinra in combination with high-dose methylprednisolone and intravenous immunoglobulins. Especially the use of high dosages of …
Hyperferritinemic sepsis, macrophage activation syndrome, and …
Sep 6, 2023 · From this, we infer that IL-1β inhibition by Anakinra might decrease hyperferritinemia and MAS. Our research network is presently enrolling children in the targeted …
Towards personalized medicine: a scoping review of …
May 28, 2024 · One of the RCTs studying anakinra in 696 sepsis patients, failed to demonstrate a mortality reduction, however in a post-hoc analysis treatment with anakinra provided a 30% …
Blocking IL-1 to prevent respiratory failure in COVID-19
Jul 18, 2020 · Anakinra is a bio-engineered form of the naturally occurring interleukin-1 receptor antagonist (IL-1ra) that blocks the action of interleukin-1 (Fig. 1). It is routinely used in patients …
Targeting the host response in sepsis: current approaches and …
Dec 6, 2023 · Anakinra treatment provided higher odds for clinical improvement and lowered the 28-day mortality from 6.9 to 3.2%. SuPAR and MAS features illustrate the biological and …
Towards precision medicine for sepsis patients - Critical Care
Jan 12, 2017 · Indeed, the interleukin (IL)-1 receptor blockade phase 3 trial published in 1997 showed no effect of immune suppression with anakinra on mortality in patients suffering from …
Feb 27, 2024 · Conclusion We identify an association between endotypes dened using blood transcriptome and anakinra therapy for COVID‑19 pneumonia, with anakinra‑treated patients …